title: SPIRIT Women, evaluation of the safety and efficacy of the XIENCE V everolimus-eluting stent system in female patients: referral time for coronary intervention and 2-year clinical outcomes.
abstract: OBJECTIVE
  SPIRIT Women is the first interventional trial dedicated exclusively to women, focusing on symptoms at presentation, referral time to coronary intervention and the safety and performance of the XIENCE V stent.
  
  
  RESULTS
  SPIRIT Women is a prospective, open-label, multicentre study in which 1,573 women were enrolled at 73 sites outside the United States. The primary endpoint is the composite of all death, Academic Research Consortium (ARC) defined myocardial infarction (MI) and target vessel revascularisation (TVR) at one year. Data collected included symptoms at presentation and referral to coronary intervention. To allow comparison by gender, the latter were compared to data from male patients from the SPIRIT V study. The one- and two-year composite of all death, MI and TVR was 12% and 15%, respectively. Target lesion revascularisation (TLR) and stent thrombosis (definite and probable) rates were 2.4% and 0.59%, respectively, at one year and 3.6% and 0.73%, at two years. The total referral time for coronary intervention in women was four days longer than for men in the SPIRIT V study.
  
  
  CONCLUSIONS
  The XIENCE V stent is safe and effective with low TLR and stent thrombosis rates. More efforts remain to be made to increase the awareness of women and physicians of the risk for coronary artery disease (CAD).
authors: Institut Cardiovasculaire Paris Sud, Paris, France. mc.morice@icps.com.fr
authors: Marie-Claude
authors: MC
authors: Morice
authors: Ghada W
authors: GW
authors: Mikhail
authors: Fina
authors: F
authors: Mauri i Ferré
authors: Maria Grazia
authors: MG
authors: Modena
authors: Ruth H
authors: RH
authors: Strasser
authors: Liliana
authors: L
authors: Grinfeld
authors: Krishnankutty
authors: K
authors: Sudhir
authors: Marrianne
authors: M
authors: Stuteville
authors: Peggy
authors: P
authors: Papeleu
authors: Dong
authors: D
authors: Li
authors: David
authors: D
authors: Rutledge
authors: Stephan
authors: S
authors: Windecker
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D003324:Coronary Artery Disease / Q000209:etiology / Q000628:therapy*; D023903:Coronary Restenosis; D054855:Drug-Eluting Stents / Q000009:adverse effects; D000068338:Everolimus; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012017:Referral and Consultation / Q000706:statistics & numerical data; D012307:Risk Factors; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000068338:Everolimus; D020123:Sirolimus